Heart-kidney relationship

The **heart–kidney relationship** refers to the complex physiological and pathological interactions between the cardiovascular system and renal system. These two organs maintain circulatory homeostasis through tightly linked hemodynamic, neurohormonal, inflammatory, and metabolic pathways. Dysfunction in one organ can induce dysfunction in the other—a phenomenon clinically recognized as **cardiorenal syndrome**. For example: When cardiac output falls due to heart failure, reduced renal perfusion leads kidneys to activate compensatory mechanisms such as renin–angiotensin–aldosterone system (RAAS) activation. This increases blood pressure but also sodium/water retention—further stressing both organs. Conversely, chronic kidney disease can drive hypertension and release factors like FGF23 that promote cardiac hypertrophy. Inflammation plays an important role in this cross-talk; cytokines released during acute injury in either organ can damage the other. Recent research has identified shared molecular signatures—including cell cycle regulators like CDK2 and CCND1—that may serve as biomarkers or therapeutic targets for combined heart/kidney dysfunction. However, these findings relate more broadly to pathophysiology than any single druggable protein. The term "heart–kidney relationship" does **not** refer to a discrete molecule or receptor but rather describes an inter-organ network involving multiple signaling molecules (such as angiotensin II), hormones (aldosterone), growth factors (FGF23), inflammatory mediators (TNFα/IL6), cell types (fibroblasts/myofibroblasts), transcription factors (YAP/TAZ), uremic toxins from gut microbiota, etc. Because it is not a defined protein/receptor/enzyme/transporter/transcription factor/etc., it should **not be considered a canonical therapeutic target**, nor does it have standard abbreviations or aliases typical of drug targets. If you are seeking information on actionable targets within this axis—for example “angiotensin II type 1 receptor” or “fibroblast growth factor 23”—those would be appropriate canonical entries. In summary: The "Heart–kidney relationship" is *not* itself a valid molecular drug target but rather describes systemic physiological interactions underlying cardiorenal syndromes.

Other names

Cardiorenal syndromeHeart-kidney axisCardiac-renal interactionKidney-heart connection